Nephron Research analyst Thomas DeBourcy upgraded CareDx (CDNA) to Buy from Hold with a $28 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDNA:
- CareDx’s HeartCare Study: A Game Changer in Transplant Monitoring?
- CareDx’s ALAMO Study: A Game Changer in Lung Transplant Surveillance?
- CareDx’s ALAMO Study: A New Era in Lung Transplant Surveillance
- CareDx’s HeartCare Study: A Game-Changer in Transplant Surveillance?
- CareDx Stockholders Approve Key Proposals at Annual Meeting